Processa Pharmaceuticals (PCSA) Liabilities and Shareholders Equity (2012 - 2026)

Processa Pharmaceuticals (PCSA) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $4.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 6.0% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.1 million (up 36.53% YoY) and the FY2025 annual result came in at $7.8 million, up 141.96% from the prior year.
• Liabilities and Shareholders Equity declined to $4.5 million in Q1 2026, from $7.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $24.3 million in Q1 2022 to a low of $3.2 million in Q4 2024.
• A 5-year average of $9.9 million and a median of $8.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 67.43% — and 2025, when it jumped 141.96%.
• Tracing PCSA's Liabilities and Shareholders Equity over 5 years: stood at $8.6 million in 2022, then tumbled by 32.87% to $5.8 million in 2023, then sank by 44.19% to $3.2 million in 2024, then jumped by 141.96% to $7.8 million in 2025, then tumbled by 42.14% to $4.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $4.5 million (Q1 2026), $7.8 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.